Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Viatris Inc. (VTRS) — XLV Health Care · S&P 500 Profile |暉致公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Viatris Inc. (VTRS) — Business, History & S&P 500 Profile |暉致公司介紹

Viatris company profile · branded and generic medicines · history · financial snapshot · S&P 500 rank #389 · 暉致公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 3, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$21.73B
Nov 3, 2026 (StockAnalysis)
S&P 500 WEIGHT
0.03%
Rank #389 · Nov 3, 2026 (Slickcharts)
FY2025 TOTAL REVENUES
$14,299.9m
-3% YoY (10-K)
FY2025 NET LOSS
$(3,514.9)m
Diluted EPS $(3.00) · incl. $2.9B impairment

SNAPSHOT

TickerVTRS (Nasdaq)
CompanyViatris Inc.
GICS sector / industryHealth Care / Pharmaceuticals
S&P 500 rank (by weight)#389 · 0.03% (Nov 3, 2026)
Sector rank (by S&P 500 weight)#48 in Health Care (Nov 3, 2026)
HeadquartersCanonsburg, Pennsylvania
FoundedNovember 16, 2020 (merger of Mylan and Upjohn)
CEOScott A. Smith (since April 1, 2023)
EmployeesApproximately 30,000
Market cap$21.73B (Nov 3, 2026)
SEC filingsEDGAR — CIK 1792044

WHAT IT DOES

Viatris is a global healthcare company that bridges brands and generics: it sells off-patent branded medicines, complex generics, biosimilars and over-the-counter products in more than 165 countries, built on a portfolio of more than 1,400 approved molecules. It was formed on November 16, 2020, when Pfizer’s Upjohn business merged with Mylan in a Reverse Morris Trust transaction.

The company reports by geography, not by product type: Developed Markets (North America and Europe), Greater China, JANZ (Japan, Australia and New Zealand) and Emerging Markets. By product category in FY2025, Brands contributed $9,184.0m of net sales (about flat year over year) and Generics $5,066.4m (down 8%), and new-product revenues were approximately $324m for the year.

In 2025 Viatris completed an enterprise-wide strategic review, expecting $650m of total cost savings with reinvestment of up to $250m over three years, and returned more than $1 billion to shareholders. In October 2026 it announced the acquisition of Pacira Biosciences for $1.65 billion, expected to close by the end of 2026 subject to conditions — a post-fiscal-year event not reflected in the FY2025 financial statements.

NET SALES BY SEGMENT — FY2025

SegmentNet salesShareYoY
Developed Markets$8,514.0m59.7%-5%
Greater China$2,332.5m16.4%+8%
JANZ$1,193.8m8.4%-11%
Emerging Markets$2,210.1m15.5%-2%
Total net sales$14,250.4m100%-3%
Source: Viatris FY2025 Form 10-K (fiscal year ended Dec 31, 2025), segment results as presented in the full-year 2025 earnings release. Shares are computed from the segment net sales. YoY percentages are the reported changes as disclosed. Total revenues were $14,299.9m, which exceeds total net sales by $49.5m of other revenues (computed difference).

HISTORY

YearMilestone
1886The Upjohn Company founded in Kalamazoo, Michigan (Upjohn predecessor)
1961Mylan founded by Milan Puskar and Don Panoz
2020Viatris formed on November 16, 2020, by the merger of Mylan and Pfizer’s Upjohn business; Michael Goettler becomes first chief executive officer
2023Scott A. Smith becomes chief executive officer on April 1, 2023, succeeding Michael Goettler
2025Enterprise-wide strategic review completed; $2.9 billion goodwill impairment recognised at the March 31, 2025 interim test
2026Acquisition of Pacira Biosciences for $1.65 billion announced on October 12, 2026, expected to close by end of 2026

COMPETITIVE POSITION

  • Scale in off-patent medicines is the asset: more than 1,400 approved molecules, manufacturing in the U.S., India and Europe, and commercial reach in 165-plus countries give Viatris breadth that pure generics specialists cannot match.
  • The FY2025 mix tells the story: Brands held flat at $9,184.0m while Generics fell 8% to $5,066.4m, so the company’s future depends on defending brands and launching new products (about $324m of new-product revenues in 2025) faster than generics erode.
  • Competition is Teva, Sandoz, Sun Pharma and Dr. Reddy’s in generics, plus branded-pharma owners defending their own loss-of-exclusivity franchises.
  • Geography cuts both ways: Greater China grew 8% in FY2025, but JANZ fell 11% on Japanese price regulation and generic competition, and Developed Markets fell 5% on North American generic pressure.
  • Cash generation versus GAAP profit is the central tension: adjusted EBITDA was $4,160.0m and adjusted EPS $2.35 in FY2025, against a $3,514.9m GAAP net loss — investors must decide which series describes the business.

FINANCIAL SNAPSHOT — FY2025 (10-K)

Total revenues$14,299.9m
Total net sales$14,250.4m
Gross profit$5,013.5m
Operating income$254m
Net loss$(3,514.9)m
Diluted EPS$(3.00)
Adjusted EBITDA (non-GAAP)$4,160.0m
Adjusted EPS (non-GAAP)$2.35
Source: Viatris Form 10-K for the fiscal year ended Dec 31, 2025. The GAAP net loss includes the previously disclosed $2.9 billion goodwill impairment charge from the interim test performed as of March 31, 2025. U.S. GAAP net cash provided by operating activities was $2,315.9m; free cash flow excluding transaction costs was $2.2 billion. Adjusted EBITDA and adjusted EPS are non-GAAP measures and are not substitutes for GAAP results.

KEY RISKS

  • Impairment overhang: the $2.9 billion Q1 2025 goodwill impairment shows how much of the balance sheet still depends on merger-era valuations; further tests could repeat it.
  • Loss of exclusivity and generic competition: expected competition on certain North American products and new launches elsewhere cut Generics sales 8% in FY2025.
  • Government price regulation: China volume-based procurement and Japanese price revisions directly set prices in two of the four segments.
  • Manufacturing quality and disruption: a February 2026 fire suspended manufacturing at the Nashik, India oral-solid-dose facility, with resumption expected from April 2026 — a post-fiscal-year event that illustrates plant-concentration risk.
  • Leverage and uncovered dividend: GAAP losses do not cover the dividend; the payout rests on operating cash flow ($2,315.9m in FY2025) and adjusted earnings, not on GAAP profit.
  • Pipeline execution: 2026 guidance depends on six expected regulatory decisions and $450m–$550m of new-product revenues; delays would reopen the growth question.

WHY IT MATTERS FOR THE S&P 500

Viatris is the S&P 500 health-care name where revenue and weight diverge most in this batch: $14.3 billion of sales against a $21.73 billion capitalisation and a #389 rank — the market prices it as a melting ice cube, not as a growth stock.

For the index, it is the test of whether an off-patent portfolio can be stabilised: if brands hold and new products scale, the gap between its $14.3 billion revenue base and its 0.03% weight closes; if generics erosion continues, the weight is telling the truth.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 3, 2026 crawl) · StockAnalysis (market cap — Nov 3, 2026 crawl, single source)
FinancialsViatris Inc. Form 10-K for the fiscal year ended December 31, 2025 (filed February 2026)
Sector classificationGICS via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

Viatris

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號VTRS(Nasdaq)
公司Viatris Inc.
GICS 板塊/行業醫療保健/Pharmaceuticals
標普500排名(按權重)第389名 · 0.03%(2026 年 11 月 3 日)
板塊內排名(按標普500權重)醫療保健第48名(2026 年 11 月 3 日)
總部賓夕法尼亞州卡農斯堡
成立2020年11月16日(Mylan 與 Upjohn 合併)
行政總裁Scott A. Smith(2023年4月1日起)
員工約30,000人
市值$21.73B(2026 年 11 月 3 日)
SEC 文件EDGAR — CIK 1792044

業務概覽

暉致是一家橫跨品牌藥及學名藥的全球醫療保健公司,在逾 165 個國家銷售專利屆滿品牌藥、複雜學名藥、生物相似藥及非處方產品,組合涵蓋逾 1,400 個已獲批分子。公司於 2020 年 11 月 16 日成立,由輝瑞的 Upjohn 業務與 Mylan 以反向莫里斯信託交易合併而成。

公司按地區而非產品類型列報:Developed Markets(北美及歐洲)、Greater China、JANZ(日本、澳洲及新西蘭)及 Emerging Markets。按產品類別計,2025 財年 Brands 淨銷售額為 91.840 億美元(按年大致持平),Generics 為 50.664 億美元(下跌 8%);全年新產品收入約 3.24 億美元。

2025 年,暉致完成全企業策略檢討,預期三年內節省合共 6.50 億美元成本,並再投資最多 2.50 億美元;全年向股東返還逾 10 億美元。2026 年 10 月,公司公布以 16.5 億美元收購 Pacira Biosciences,預計於 2026 年底前完成(須符合若干條件)——此為財年結束後事件,並未反映於 2025 財年財務報表。

按分部劃分的淨銷售額 — 2025 財年

板塊淨銷售額佔比同比
Developed Markets85.140億美元59.7%-5%
Greater China23.325億美元16.4%+8%
JANZ11.938億美元8.4%-11%
新興市場22.101億美元15.5%-2%
淨銷售總額142.504億美元100%-3%
來源:暉致 2025 財年 Form 10-K(截至 2025 年 12 月 31 日的財年)分部業績(按 2025 全年業績公布呈列)。佔比由分部淨銷售額計算;同比百分比為披露的申報變動。總收入為 142.999 億美元,較淨銷售總額高出 0.495 億美元其他收入(計算得出的差額)。

歷史沿革

年份里程碑
1886年Upjohn Company 在密歇根州卡拉馬祖成立(Upjohn 前身)
1961年Mylan 由 Milan Puskar 及 Don Panoz 創立
2020年暉致於 2020 年 11 月 16 日由 Mylan 與輝瑞 Upjohn 業務合併而成;Michael Goettler 出任首任行政總裁
2023年Scott A. Smith 於 2023 年 4 月 1 日出任行政總裁,接替 Michael Goettler
2025年完成全企業策略檢討;於 2025 年 3 月 31 日中期測試確認 29 億美元商譽減值
2026年於 2026 年 10 月 12 日公布以 16.5 億美元收購 Pacira Biosciences,預計於 2026 年底前完成

競爭地位

  • 專利屆滿藥物的規模即資產:逾 1,400 個已獲批分子、在美國、印度及歐洲的生產基地,以及遍及 165 多個國家的商業網絡,令暉致的廣度為純學名藥專門企業無法比擬。
  • 2025 財年的組合說明一切:Brands 淨銷售額持平於 91.840 億美元,Generics 則下跌 8% 至 50.664 億美元,故公司未來取決於能否捍衛品牌藥、並以快於學名藥侵蝕的速度推出新產品(2025 年新產品收入約 3.24 億美元)。
  • 競爭來自學名藥方面的 Teva、Sandoz、Sun Pharma 及 Dr. Reddy’s,以及為自身專利屆滿產品辯護的品牌藥廠。
  • 地區表現好壞參半:2025 財年 Greater China 增長 8%,但 JANZ 因日本價格監管及學名藥競爭下跌 11%,Developed Markets 亦因北美學名藥壓力下跌 5%。
  • 現金產生與公認會計原則利潤之間的張力是核心:2025 財年經調整 EBITDA 為 41.600 億美元、經調整每股盈利 2.35 美元,對比公認會計原則淨虧損 35.149 億美元——投資者須判斷哪組數字更能描述業務。

財務快照 — 2025 財年(10-K)

總收入142.999億美元
淨銷售總額142.504億美元
毛利50.135億美元
經營利潤2.54億美元
淨虧損(35.149億美元)
攤薄每股盈利(3.00美元)
經調整 EBITDA(非公認會計原則)41.600億美元
經調整每股盈利(非公認會計原則)2.35美元
來源:暉致截至 2025 年 12 月 31 日財年的 Form 10-K。公認會計原則淨虧損包括此前披露的 29 億美元商譽減值支出(來自 2025 年 3 月 31 日中期測試)。公認會計原則經營活動提供的現金淨額為 23.159 億美元;不包括交易成本的自由現金流為 22 億美元。經調整 EBITDA 及經調整每股盈利為非公認會計原則指標,不能代替公認會計原則業績。

主要風險

  • 減值陰霾:2025 年第一季 29 億美元商譽減值顯示,資產負債表仍有多大程度依賴合併時期的估值;進一步測試可令情況重演。
  • 專利屆滿及學名藥競爭:北美若干產品預期面對競爭,加上其他地區的新產品推出,令 2025 財年 Generics 銷售下跌 8%。
  • 政府價格監管:中國帶量採購及日本價格修訂直接決定四個分部其中兩個的價格。
  • 生產質素及中斷:2026 年 2 月一場火災令印度 Nashik 口服固體製劑廠房暫停生產,預計自 2026 年 4 月起恢復——此為財年結束後事件,說明工廠集中風險。
  • 槓桿及未獲盈利覆蓋的股息:公認會計原則虧損未能覆蓋股息;派息依賴經營現金流(2025 財年為 23.159 億美元)及經調整盈利,而非公認會計原則利潤。
  • 產品線執行:2026 年指引依賴六項預期監管決定及 4.50 億至 5.50 億美元新產品收入;一旦延誤,增長問題將再度浮現。

對標普500的重要性

暉致是本批中收入與權重分歧最大的標普 500 醫療保健名稱:銷售額 143 億美元,對比市值 217.3 億美元及第 389 名排名——市場將其定價為正在融化的冰塊,而非增長股。

對指數而言,它是專利屆滿組合能否穩定的檢驗:若品牌藥守得住、新產品擴大規模,其 143 億美元收入基礎與 0.03% 權重之間的差距便會收窄;若學名藥侵蝕持續,則權重說的是實話。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 3 日抓取)· StockAnalysis(市值——2026 年 11 月 3 日抓取,單一來源)
財務Viatris Inc. 截至 2025 年 12 月 31 日財年的 Form 10-K(2026 年 2 月提交)
板塊分類GICS,據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

Viatris

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · VTRS
Data as of Nov 3, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Old Dominion Freight Line, Inc. (ODFL) — XLI Industrials · S&P 500 Profile |Old Dominion Freight Line公司介紹Next · Amcor plc (AMCR) — XLB Materials · S&P 500 Profile |安姆科公司介紹

Entered 2026-11-03 18:04 · updated 2026-11-15 00:15 · rev 5